Tumor Expression of Human Growth Hormone and Human Prolactin Predict a Worse Survival Outcome in Patients with Mammary or Endometrial Carcinoma | Zendy

Zhengsheng Wu | Zendy; Kun Yang | Zendy; Yu Wan | Zendy; Pengxu Qian | Zendy; Jo K. Perry | Zendy; Jean Chiésa | Zendy; Hichem C. Mertani | Zendy; Tao Zhu | Zendy; Peter E. Lobie | Zendy

Open Access

Tumor Expression of Human Growth Hormone and Human Prolactin Predict a Worse Survival Outcome in Patients with Mammary or Endometrial Carcinoma

Author(s) -

Zhengsheng Wu,

Kun Yang,

Yu Wan,

Pengxu Qian,

Jo K. Perry,

Jean Chiésa,

Hichem C. Mertani,

Tao Zhu,

Peter E. Lobie

Publication year - 2011

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-1245

Subject(s) - prolactin , autocrine signalling , paracrine signalling , context (archaeology) , medicine , hormone , carcinoma , endometrial cancer , human breast , endocrinology , biology , oncology , cancer research , cancer , breast cancer , receptor , paleontology

Evidence suggests that human GH (hGH) and human prolactin (hPRL) possess an autocrine or paracrine oncogenic role in mammary and endometrial carcinoma. However, especially for hGH, the prognostic relevance of tumor expression of these hormones is not well defined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research